Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620532 | 0.68 | EDNRA (0.43) | MEN1KMT2A | |
| SCHEMBL28733623 | 0.63 | CYP1A2 (0.48) | MEN1KMT2A | |
| SCHEMBL6310489 | 0.57 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL3015790 | 0.55 | CYP1A2 (0.48) | MEN1KMT2A | |
| SCHEMBL7065132 | 0.51 | GLRA3 (0.46) | MEN1KMT2A | |
| SCHEMBL14989129 | 0.51 | GLRA3 (0.46) | MEN1KMT2A | |
| SCHEMBL16899793 | 0.51 | CYP1A2 (0.42) | — | |
| SCHEMBL2996746 | 0.50 | CYP1A2 (0.41) | MEN1KMT2A | |
| SCHEMBL28337231 | 0.50 | GLRA3 (0.44) | MEN1KMT2A | |
| SCHEMBL31472801 | 0.49 | GLRA3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720433-B2 | MOTILIN RECEPTOR ANTAGONIST; PHE-N-ME-VAL-(3-(3-METHYLINDOL-5-YL))ALA-NH2;PHE-N-ME-VAL-PHE( 3-ACETYL-4-HYDROXY)-NH2;PHE-N-ME-VAL-(3-(5-TERT-BUTYL-4-SULFAM OYL-2-FURYL))ALA-NH2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | disclosed |
| US-6586630-B1 | Carbocyclic carboxy amines, used as motilin receptor antagonists for therapy of gastrointerstinal disorders such as irritable bowel syndrome; hormone inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176643-A1 | Ethylamine derivatives | MLNR, GIPR, MC4R | MEN1 359/4885KMT2A 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.